Does combination therapy work in chronic thromboembolic pulmonary hypertension?

M C J van Thor; R J Snijder; J C Kelder; J J Mager; M C Post

doi:10.1016/j.ijcha.2020.100544

Does combination therapy work in chronic thromboembolic pulmonary hypertension?

Int J Cardiol Heart Vasc. 2020 Jun 3:29:100544. doi: 10.1016/j.ijcha.2020.100544. eCollection 2020 Aug.

Authors

M C J van Thor¹, R J Snijder², J C Kelder³, J J Mager², M C Post^{1

4}

Affiliations

¹ Dept of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
² Dept of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.
³ Dept of Epidemiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
⁴ Dept of Cardiology, Utrecht University Medical Center, Utrecht, the Netherlands.

Abstract

Objective: The current experience with combination therapy in chronic thromboembolic pulmonary hypertension (CTEPH) is limited. We present the first survival results up to 5 years for dual combination therapy versus monotherapy in CTEPH.

Methods: All consecutive, non-operated CTEPH or residual PH after pulmonary endarterectomy patients treated with PH-specific medical therapy between January 2002 and November 2019 were included. We report and compare survival between monotherapy and (upfront or sequential) dual combination therapy until five years after medication initiation.

Results: In total, 183 patients (mean age 65 ± 14 years, 60% female, 66% WHO FC III/IV, 86% non-operated) were included, of which 83 patients received monotherapy and 100 patients received dual combination therapy. At baseline, patients receiving combination therapy had a higher NT-proBNP (p = 0.02) mean pulmonary artery pressure (p = 0.0001) and pulmonary vascular resistance (p = 0.02), while cardiac index was lower (p = 0.03). Total follow-up duration was 3.3 ± 1.8 years, during which 31 (17%) patients died. Estimated 1-, 3- and 5-year survival for monotherapy were 99%, 92% and 79%, respectively. For combination therapy percentages were 98%, 89% and 70%, respectively. Survival did not significantly differ between both groups (p = 0.22).

Conclusion: Survival up to 5 years for patients treated with combination therapy, regardless of the combination strategy, was similar as patients with monotherapy, despite worse clinical and haemodynamic baseline characteristics.

Keywords: 6MWD, 6-minute walking distance; BPA, balloon pulmonary angioplasty; CI, cardiac index; CO, cardiac output; COPD, chronic obstructive lung disease; CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension; Chronic thromboembolic pulmonary hypertension; Combination therapy; ERA(s), endothelin receptor antagonist(s); FC, functional class; HR, hazards regression; IQR, interquartile range; Monotherapy; NT-proBNP, N-terminal pro brain natriuretic peptide; PAH, pulmonary arterial hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RHC, right heart catheterisation; SD, standard deviation; Survival; WHO, World Health Organization; mPAP, mean pulmonary arterial pressure.